

The Omicron variant is now the prevalent variant in Maine, and as such, the ME CDC is **recommending that healthcare providers suspend the use of two monoclonal antibody therapies, bamlanivimab/etesevimab ("bam-ete") and casirivimab/imdevimab (REGEN-COV) for treatment of COVID-19.** Sotrovimab, remains effective against the Omicron variant and will continue to be offered to patients meeting criteria. **DECH does not have Sotrovimab on hand.** You may contact the other listed mAb infusion centers for availability of Sotrovimab https://www.maine.gov/dhhs/mecdc/infectious-disease/epi/airborne/coronavirus/mAb_ME%20Providers.pdf